, Tracking Stock Market Picks
Enter Symbol:
Clovis Oncology Inc (CLVS) [hlAlert]

up 259.71 %

Clovis Oncology Inc (CLVS) rated Outperform by Leerink Swann

Posted on: Wednesday,  Sep 19, 2012  8:25 AM ET by Leerink Swann

Leerink Swann rated Outperform Clovis Oncology Inc (NASDAQ: CLVS) on 09/19/2012, when the stock price was $21.15.
Since then, Clovis Oncology Inc has gained 259.72% as of 01/20/2016's recent price of $76.08.
If you would have followed this Leerink Swann 's recommendation on CLVS, you would have gained 259.71% of your investment in 1218 days.

Clovis Oncology, Inc. (Clovis) is a Development-stage Company. The Company is a Biopharmaceutical Company. The Company focuses on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company also focuses on the treatment of specific subsets of cancer populations. During the year ended December 31, 2010, the Company was in the process of developing three product candidates for which it holds global marketing rights: CO-101, a lipid-conjugated form of the anti-cancer drug gemcitabine; CO-1686, an oral epidermal growth factor receptor (EGFR) mutant-selective inhibitor and CO-338, a poly ADP (Adenosine Diphosphate)-ribose polymerase (PARP) inhibitor.

Leerink Swann Equity Research provides unique perspectives and agenda-setting healthcare recommendations for investors. Supported by industry-based intelligence and thorough market examination, our proprietary research enables our clients to make well-informed healthcare investment decisions. Our investment perspectives are driven by proprietary insights from MEDACorp. MEDACorp's more than 25,000 network professionals work with new and/or development-stage pharmaceuticals, medical devices and biotherapeutics on a daily basis. MEDACorp's extensive knowledge of products and research enables Leerink Swann to provide growth-focused clients an expertise earned through experience.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
9/19/2012 8:25 AM Buy
as of 12/31/2012
1 Week up  2.76 %
1 Month up  4.03 %
3 Months down  -21.76 %
1 YTD down  -24.34 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy